



HUTCHISON CHINA MEDITECH LTD

For Immediate Release

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Change in the Registered Office Address in the Cayman Islands

London, 28 February 2008: Chi-Med announces that due to the change in the address system in the Cayman Islands and the adoption of a new postal code as mandated by the Cayman government, the registered office address of Chi-Med in the Cayman Islands is changed to P.O. Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands. The physical location of the registered office remains unchanged.

Ends

Enquiries

Chi-Med Telephone: +852 2121 8200
Christian Hogg, CEO

Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571
Anthony Carlisle +44 (0) 7973 611 888
David Dible +44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine (“TCM”) based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business segments: 1) China healthcare – the manufacture, distribution and marketing of pharmaceuticals and health supplements in China; 2) Drug R&D – the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer products – global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.